Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women

NCT01041092 is registered in ClinicalTrials.gov with Fundació Sant Joan de Déu as lead sponsor.

NCT NCT01041092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01041092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women
Lead sponsor
Fundació Sant Joan de Déu
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2004
Completion date
December 31, 2009
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia